Indivior (NASDAQ:INDV) Trading Down 5.6%

Indivior PLC (NASDAQ:INDV) dropped 5.6% on Friday . The stock traded as low as $10.70 and last traded at $10.70. Approximately 471,105 shares were traded during mid-day trading, an increase of 181% from the average daily volume of 167,390 shares. The stock had previously closed at $11.33.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum dropped their target price on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday.

Indivior Price Performance

The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.74 and a current ratio of 0.92. The stock has a market capitalization of $1.48 billion, a PE ratio of 1,071.00 and a beta of 0.69. The stock’s 50 day moving average is $16.55 and its two-hundred day moving average is $17.96.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a net margin of 0.44% and a return on equity of 842.72%. The firm had revenue of $284.00 million during the quarter, compared to analysts’ expectations of $300.00 million. On average, equities analysts anticipate that Indivior PLC will post 1.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Indivior

Large investors have recently modified their holdings of the business. Chilton Investment Co. Inc. purchased a new position in shares of Indivior in the fourth quarter worth about $263,000. ADAR1 Capital Management LLC acquired a new stake in Indivior in the 4th quarter valued at about $368,000. Cannon Global Investment Management LLC acquired a new stake in Indivior in the 1st quarter valued at about $563,000. Forsta AP Fonden purchased a new position in Indivior in the 1st quarter worth approximately $641,000. Finally, Campbell & CO Investment Adviser LLC boosted its holdings in shares of Indivior by 2.8% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after purchasing an additional 1,037 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.